Press Release relating to FDA Approval for SALONPASR PAIN RELEAF PATCH(code: FS-67, topical analgesic product) under NDA

The Company's Official Page[PDF]
http://www.hisamitsu.co.jp/english/pdf/FS67_E_080222.pdf
Back To Previous Page


February 22, 2008
Hisamitsu Pharmaceutical Co., Inc.
Press Release relating to FDA Approval for SALONPAS
®
PAIN RELEAF PATCH
(code: FS-67, topical analgesic product) under NDA
Hisamitsu Pharmaceutical Co., Inc. (Representative Director, President and CEO: Hirotaka Nakatomi, “Hisamitsu”) announced today that the company has obtained the U.S. FDA approval for its newly developed topical analgesic product, SALONPAS

Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. Notice Regarding Worldwide Patent and Kn...
Mitsubishi Tanabe Pharma Corporation 2015/09/17
2. Announcement of FY2015 2nd Quarter Finan...
Mitsubishi Tanabe Pharma Corporation 2015/10/30
3. Mitsubishi Tanabe Pharma Enhances Operat...
Mitsubishi Tanabe Pharma Corporation 2016/02/23
4. Notice of Dividend of Retained Earnings
Mitsubishi Tanabe Pharma Corporation 2016/05/11
5. Approval of REMICADE for I.V. Infusion 1...
Mitsubishi Tanabe Pharma Corporation 2016/05/13

Latest News: Hisamitsu Pharmaceutical Co., Inc.


Most Popular: Hisamitsu Pharmaceutical Co., Inc.

1. Notice concerning acquisition result and...
2009/12/11

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us